Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use
Lauren Veltri(West Virginia University), Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Sijin Wen(The University of Texas MD Anderson Cancer Center), Sonia Leadmon(West Virginia University), Michael Craig(Edith Cowan University), Aaron Cumpston(West Virginia University Hospitals), Luo Jin(West Virginia University), Alexandra Shillingburg(West Virginia University)
Cited by 33
Related Papers
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
|Proceedings of the National Academy of Sciences|2007|517
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441